{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:30:18Z","timestamp":1785353418231,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijantimicag.2021.106441","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T02:31:24Z","timestamp":1632105084000},"page":"106441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013\u20132018 Compared to 2004\u20132012: Results from the ATLAS Surveillance Study"],"prefix":"10.1016","volume":"58","author":[{"given":"Harald","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"von Linstow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2021.106441_bib0001","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/INF.0b013e3182886377","volume":"32","author":"Badal","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QCO.0000000000000371","article-title":"Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment","volume":"30","author":"Folgori","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jpids\/piu014","article-title":"Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries","volume":"4","author":"Le Doare","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/501755","article-title":"Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group","volume":"21","author":"Raymond","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0006","doi-asserted-by":"crossref","first-page":"dlaa066","DOI":"10.1093\/jacamr\/dlaa066","article-title":"Healthcare-associated bacterial infections in the paediatric ICU","volume":"2","author":"Akinkugbe","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0007","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0080","article-title":"Surveillance of antibiotic resistance","volume":"370","author":"Johnson","year":"2015","journal-title":"Phil Trans R Soc B"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0008","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ijantimicag.2019.01.015","article-title":"Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme","volume":"53","author":"Shortridge","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0009","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1128\/JCM.03184-14","article-title":"Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial","volume":"53","author":"Kehl","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0010","unstructured":"ATLAS Surveillance. Antimicrobial Testing Leadership and Surveillance, https:\/\/atlas-surveillance.com ; 2020 [accessed 10 August 2020]."},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0011","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020, https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf ; 2020 [accessed 23 September 2020]."},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ijerph16010027","article-title":"Drivers of irrational use of antibiotics in Europe","volume":"16","author":"Machowska","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0013","series-title":"Annual epidemiological report for 2018","article-title":"European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU\/EEA","year":"2018"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0014","first-page":"72","article-title":"Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014","volume":"6","author":"Lob","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0015","series-title":"Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","article-title":"European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe 2018","year":"2018"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0016","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.9.1900123","article-title":"Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018","volume":"24","author":"Brolund","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijantimicag.2006.09.012","article-title":"High activity of meropenem against Gram-negative bacteria from a paediatric Intensive Care Unit, 2001-2005","volume":"29","author":"Patzer","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13756-020-00750-5","article-title":"The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017","volume":"9","author":"Ayobami","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2021.106441_bib0019","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diagmicrobio.2006.07.003","article-title":"Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents","volume":"56","author":"Fedler","year":"2006","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921007226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921007226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:41:00Z","timestamp":1760377260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921007226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0924857921007226"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106441","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013\u20132018 Compared to 2004\u20132012: Results from the ATLAS Surveillance Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106441"}}